Aquestive Therapeutics is a technology company.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies.
Aquestive Therapeutics is a pharmaceutical company specializing in innovative drug delivery via its proprietary PharmFilm® technology, which develops thin, dissolvable oral films for complex molecules, offering non-invasive alternatives to injections or inconvenient therapies.[1][2][3][4] It serves patients with central nervous system (CNS) disorders, severe allergies like anaphylaxis, and other conditions requiring rapid, patient-friendly administration, addressing unmet needs through a pipeline of investigational treatments and four FDA-approved commercialized products manufactured exclusively for licensees.[1][2][4] The company's mission is to improve patient lives by advancing innovative medicines using advanced delivery technologies, with a vision to pioneer oral transmucosal delivery and expand its portfolio in CNS and allergy areas, evidenced by over 2 billion doses delivered and ongoing R&D investments despite projected 2025 adjusted EBITDA losses of $47-51 million.[2]
Aquestive Therapeutics emerged as a leader in oral film technology, building on the success of PharmFilm®, which has been FDA-approved for products since 2010 and powers multiple commercialized medicines launched through 2021.[1] While specific founders are not detailed in available sources, the company evolved from expertise in pharmaceutical formulation and engineering, focusing on solving real-world patient problems like barriers to medication adherence for CNS disorders and anaphylaxis.[2][3][4] Key pivotal moments include establishing a robust pipeline of investigational treatments, securing tentative FDA approvals, and partnering with pharmaceutical companies for global commercialization, positioning it as the undisputed leader in film-based drug delivery.[1][4]
Aquestive rides the trend toward patient-friendly drug delivery innovations, particularly non-invasive oral films that improve adherence and outcomes for hard-to-treat conditions like anaphylaxis and CNS disorders amid rising demand for simplified therapies.[2][3][4] Timing is ideal as market forces favor alternatives to injections in the $3.52 billion global oral thin films sector, where PharmFilm® creates high barriers to entry through its versatility for complex APIs.[2][3] The company influences the ecosystem by partnering with pharma firms, exclusively manufacturing licensed products, and expanding film technology to prodrugs, proteins, and peptides, driving broader adoption of transmucosal delivery.[1][4]
Aquestive is poised to advance its pipeline, with late-stage assets like Anaphylm targeting anaphylaxis treatment and earlier-stage dermatology candidates nearing milestones, potentially unlocking new revenue amid ongoing R&D investments.[1][2][4] Trends in personalized, non-invasive delivery and allergy/CNS unmet needs will shape its path, bolstered by PharmFilm®'s proven track record in over 2 billion doses.[2][3] Its influence may evolve through deeper partnerships and portfolio expansion, solidifying leadership in film-based medicines that simplify complex care and directly enhance patient lives.[1][4]